Opcjonalna analityka produktu
Za zgodą użytkownika stosujemy ograniczoną analitykę chroniącą prywatność, aby zrozumieć, które ścieżki badawcze działają. Nie używamy trackerów reklamowych ani nagrywania sesji. Ten wybór można zmienić w Preferencjach. Przeczytaj Politykę prywatności.
FY2027 adjusted EPS could reach $12.88.
FY2026 annual revenue growth falls below 8%.
Sell. The $137.72 report-date price is above $82.88 Fair value and $114.81 Potential value. A weak FY2026 revenue recovery is the main risk. Stronger adjusted earnings and fewer shares offer the clearest upside.4
The market quote was $137.72 on 2026-09-04 and available on 2026-09-08. House Fair value is $82.88, with Potential value of $114.81 on the 2026-09-08 analysis date.
The view worsens if FY2026 revenue growth falls below 8%. That would weaken operating leverage, adjusted earnings, and the case for improved profitability.
The constructive case requires FY2027 adjusted EPS near the $12.88 estimate. Continued share reduction is a separate condition, not a result established by the dated share observations. Fewer diluted shares would spread profit across a smaller base and raise earnings per share for the same aggregate profit.145
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.1
Sell because the report-date price exceeds both Fair value and Potential value.4
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.1
Sell because the report-date price exceeds both Fair value and Potential value.4
The central downside is an early revenue slowdown followed by weak margin conversion. Slower buybacks would then leave more shares dividing the same profit, while higher required returns would further reduce value.
This path becomes more plausible when revenue fails first and weak margin conversion follows. The result would be lower earnings per share and less willingness to pay for future profit.
FY2026 revenue growth below 8% would show that the expected rebound was weaker or more cyclical than assumed.
Provider-adjusted net margin below 18% for two post-FY2027 years would indicate that costs or business mix are absorbing the revenue recovery.
Pięć zdarzeń, które osłabiłyby naszą tezę inwestycyjną.
A breach would show that the rebound lacks expected breadth. Lower revenue would also reduce the operating leverage needed for adjusted earnings to recover faster than sales.
Obecnie:FY2026 estimate: 12.41% year over year, dated 2026-09-08.
Alarm, jeśliBelow 8% for FY2026
Citigroup has financial scale and broad geographic reach, but the evidence does not establish switching costs, network effects, proprietary integration, or another structural barrier. The recovery therefore does not support a durable moat claim.
Competition remains a conditional threat. Bank-like peers show stronger profitability, while payment and brokerage comparables have different economics. The mixed set is useful for comparison, but not as proof of direct customer losses.
The available evidence supports recovering earnings, not durable excess returns. Profitability must improve before investors can justify paying more for each dollar of future earnings.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($82.88). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $14.2B after modeled capex of $4.8B, with terminal value at 37.3% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The base path accepts the estimate-backed recovery but does not extend it indefinitely. It would weaken if post-FY2027 profitability fails to normalize or regional concentration rises materially.
A beat strengthens the short recovery but does not establish durable post-FY2027 growth.
Meeting estimates confirms recovery, but the report-date price remains above Fair value.
A miss would weaken revenue, margin, and per-share earnings together.
Judge progress through revenue, adjusted earnings, margin, and diluted shares. Bank cash movement is too influenced by balance-sheet funding to use as an industrial earnings-quality test.
Slower growth would weaken operating leverage and adjusted earnings.
For a bank, reported cash movement is shaped by loans, deposits, and funding. Industrial free-cash-flow measures therefore do not provide a reliable bridge to common-equity value.4
Capital allocation matters mainly through dividends and repurchases. The declining share count supports per-share earnings, but FY2027 diluted shares must remain below 1.8 billion for that support to persist.
The supplied return evidence supports a bank-specific assessment of book capital and shareholder returns, not a clean industrial return-on-invested-capital series.
No ROIC-versus-WACC conclusion is made. The 13.18% WACC is reserved for enterprise methods, while the bank equity analysis uses shareholder return requirements.
Adjusted diluted EPS is estimated at $12.88, while revenue is estimated at $99.52 billion, as of and retrieved on 2026-09-08.
The recovery is credible through FY2027, but later years require extrapolation.
Diluted-average shares fell from 1.9558 billion in FY2023 to 1.8731 billion in FY2025. Filing data was retrieved on 2026-09-08.
Continued reductions would support earnings per share, but the future pace is not secured.
| Przychody | 85 225 000 000 USD |
|---|---|
| Koszt sprzedaży | 10 178 000 000 USD |
| Zysk brutto | 75 047 000 000 USD |
| Koszty operacyjne | 55 219 000 000 USD |
| Zysk operacyjny | 19 828 000 000 USD |
| Pozycje pozaoperacyjne i podatki | -5 522 000 000 USD |
| Zysk netto | 14 306 000 000 USD |
| Aktywa ogółem | 2 657 202 000 000 USD |
|---|---|
| Środki pieniężne | 349 579 000 000 USD |
| Aktywa obrotowe | 738 120 000 000 USD |
| Zobowiązania ogółem | 2 443 380 000 000 USD |
| Zobowiązania krótkoterminowe | 1 530 287 000 000 USD |
| Kapitał własny | 213 822 000 000 USD |
| Zysk netto | 14 845 000 000 USD |
|---|---|
| Wpływy operacyjne | 25 069 000 000 USD |
| Amortyzacja | 4 262 000 000 USD |
| Wynagrodzenie w akcjach | 1 839 000 000 USD |
| Pozostałe korekty operacyjne | 4 123 000 000 USD |
| Operacyjne przepływy pieniężne | 25 069 000 000 USD |
| Dostępne środki pieniężne | 424 865 000 000 USD |
| Środki pieniężne na początek | 262 033 000 000 USD |
| Wpływy finansowe | 137 763 000 000 USD |
| Wydatki inwestycyjne | 79 455 000 000 USD |
| Capex | 5 632 000 000 USD |
| Pozostała działalność inwestycyjna | 73 823 000 000 USD |
| Wpływ kursów walutowych | 3 385 000 000 USD |
| Środki pieniężne na koniec | 342 025 000 000 USD |
| Przepływy inwestycyjne | -79 455 000 000 USD |
| Przepływy finansowe | 137 763 000 000 USD |
Źródło: SEC EDGAR · Złożono 2026-02-20 · SEC EDGAR
| Przychody według regionu | Przychody | Udział | r/r |
|---|---|---|---|
| International | 40,3 mld USD | 49,9% | 1,9% |
| North America | 39,7 mld USD | 49,2% | 9,2% |
| Corporate And Other Geographical | 668 mln USD | 0,8% | -68,4% |
Dane finansowe na określony moment użyte w analizie z 2026-09-08.
| Okres | Przychody | EBITDA | Zysk netto | Operacyjne przepływy pieniężne | Wolne przepływy pieniężne | Capex | Amortyzacja | Wynagrodzenie w akcjach | Skup akcji | Wypłacone dywidendy | Emisja długu netto | Przepływy inwestycyjne | Przepływy finansowe | Środki pieniężne na początek | Środki pieniężne na koniec | Gotówka i inwestycje | Zadłużenie ogółem | Marża operacyjna | ROIC | WACC | Spread ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 70,8 mld USD | 25,2 mld USD | 14,9 mld USD | 53,9 mld USD | 51,2 mld USD | 2,8 mld USD | 3,7 mld USD | 1,5 mld USD | 9,3 mld USD | 2,3 mld USD | — | -54,1 mld USD | 28,3 mld USD | — | 160,5 mld USD | 468,1 mld USD | 206,2 mld USD | 30,3% | — | 6,1% | — |
| 2017-12-31 | 72,4 mld USD | 26,4 mld USD | -6,8 mld USD | -8,8 mld USD | -12,1 mld USD | 3,4 mld USD | 3,7 mld USD | 1,6 mld USD | 14,5 mld USD | 3,8 mld USD | — | -38,8 mld USD | 66,9 mld USD | 160,5 mld USD | 180,5 mld USD | 479,5 mld USD | 236,7 mld USD | 31,4% | — | 4,8% | — |
| 2018-12-31 | 72,9 mld USD | 27,2 mld USD | 18 mld USD | 37 mld USD | 33,2 mld USD | 3,8 mld USD | 3,8 mld USD | 1,4 mld USD | 14,4 mld USD | 5 mld USD | — | -73,1 mld USD | 44,5 mld USD | 180,5 mld USD | 188,1 mld USD | 483,4 mld USD | 232 mld USD | 32,2% | — | 8,7% | — |
| 2019-12-31 | 75,1 mld USD | 27,8 mld USD | 19,4 mld USD | -12,8 mld USD | -18,2 mld USD | 5,3 mld USD | 3,9 mld USD | 6,8 mld USD | 17,6 mld USD | 5,4 mld USD | — | -23,4 mld USD | 42,9 mld USD | 188,1 mld USD | 193,9 mld USD | 474,2 mld USD | 248,8 mld USD | 31,8% | — | 8,4% | — |
| 2020-12-31 | 75,5 mld USD | 17,6 mld USD | 11 mld USD | -23,5 mld USD | -26,9 mld USD | 3,4 mld USD | 3,9 mld USD | 15,8 mld USD | 2,9 mld USD | 5,4 mld USD | — | -92,4 mld USD | 233,6 mld USD | 193,9 mld USD | 309,6 mld USD | 644,7 mld USD | 271,7 mld USD | 18,1% | — | 8,0% | — |
| 2021-12-31 | 71,9 mld USD | 31,4 mld USD | 22 mld USD | 47,1 mld USD | 43 mld USD | 4,1 mld USD | 4 mld USD | -3,7 mld USD | 7,6 mld USD | 5,2 mld USD | — | -110,7 mld USD | 17,3 mld USD | 309,6 mld USD | 262 mld USD | 541,3 mld USD | 254,4 mld USD | 38,2% | — | 3,7% | — |
| 2022-12-31 | 75,3 mld USD | 23,1 mld USD | 14,8 mld USD | 25,1 mld USD | 19,4 mld USD | 5,6 mld USD | 4,3 mld USD | 1,8 mld USD | 3,3 mld USD | 5 mld USD | 66,8 mld USD | -79,5 mld USD | 137,8 mld USD | 262 mld USD | 342 mld USD | 580,8 mld USD | 271,6 mld USD | 25,0% | — | 11,1% | — |
| 2023-12-31 | 78,1 mld USD | 17,5 mld USD | 9,2 mld USD | -73,4 mld USD | -80 mld USD | 6,6 mld USD | 4,6 mld USD | 1,8 mld USD | 2 mld USD | 5,2 mld USD | -8,8 mld USD | -8,5 mld USD | 687 mln USD | 342 mld USD | 260,9 mld USD | 506 mld USD | 286,6 mld USD | 16,5% | — | 12,3% | — |
| 2024-12-31 | 80,7 mld USD | 21,4 mld USD | 12,7 mld USD | -19,7 mld USD | -26,2 mld USD | 6,5 mld USD | 4,3 mld USD | — | 2,5 mld USD | 5,2 mld USD | 17,2 mld USD | 86,3 mld USD | -38,3 mld USD | 260,9 mld USD | 276,5 mld USD | 498 mld USD | 287,3 mld USD | 21,1% | — | 12,9% | — |
| 2025-12-31 | 85,2 mld USD | 24,2 mld USD | 14,3 mld USD | -67,6 mld USD | -74,2 mld USD | 6,5 mld USD | 4,4 mld USD | — | 13,3 mld USD | 5,4 mld USD | 22,1 mld USD | -108,3 mld USD | 238 mld USD | 276,5 mld USD | 349,6 mld USD | 675,4 mld USD | 315,8 mld USD | 23,3% | — | 10,4% | — |
Citigroup Inc. (C) trades at 10.6x forward earnings against a peer median of 12.9x. The comparison uses 4 peers: Bank of America Corporation, Wells Fargo & Company, American Express Company and The Charles Schwab Corporation, as of 2026-09-07 to 2026-09-08.
The industry capex-to-revenue benchmark was 1.8% as of 2026-09-01, retrieved that day. This does not establish a bank capacity cycle.
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.
The adverse cycle begins if FY2026 revenue growth drops below 8%. Weak sales conversion would reduce profit growth before the longer-range assumptions can take effect.
Citigroup can benefit from the near-term recovery, but the evidence supports only a short duration before mature growth resumes.
No new allocation. The report-date price exceeds Potential value, while the earnings recovery is supported only through FY2027.4
Keep exposure defensive until price and operating evidence align. Do not treat a strong quarter as proof of durable recovery beyond FY2027.
The $137.72 report-date price exceeds $82.88 Fair value and $114.81 Potential value.4
Reduce or exit because the valuation already assumes more durable profitability than the evidence supports.
Dividend capacity does not offset the valuation gap, and the dividend-based value is heavily dependent on distant assumptions.
Sell because the report-date price stands above both Fair value and Potential value.4
The near-term recovery is credible, but evidence after FY2027 is too limited to support the valuation already reflected in the shares.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
An assessed terminal P/E below 10.4x would mean profitability never earned the assumed valuation improvement.
A cost of equity above 11.1964% would reduce the present value of earnings, residual income, and dividends.2
FY2027 diluted shares above 1.8 billion would remove expected buyback support and reduce earnings per share.
Persistent weakness would indicate that costs or business mix are consuming the revenue recovery. That would lower future earnings and the value created above the required shareholder return.
Obecnie:Base forecast target: 20.0% over five years, dated 2026-09-08.
Alarm, jeśliBelow 18% for two fiscal years after FY2027
A lower multiple would show that investors still view profitability as structurally weaker. Each dollar of future earnings would then command a lower share price.
Obecnie:Base assumption: 13.0x; subject forward P/E: 10.64x on 2026-09-08.
Alarm, jeśliBelow 10.4x within 24 months
A higher required return would reduce the present value of future earnings and dividends even if operating forecasts were unchanged.
Obecnie:9.1964% on 2026-09-08, retrieved 2026-09-08T15:44:20+00:00.
Alarm, jeśliAbove 11.1964% within 12 months
A reversal would leave more shares dividing aggregate income. Earnings per share would grow more slowly, weakening one of the recovery's main supports.
Obecnie:FY2025 weighted average: 1.8731 billion; end-period count on 2026-09-08: 1.677437 billion.
Alarm, jeśliAbove 1.8 billion in FY2027
Use book value per share with normalized ROE, cost of equity, and terminal growth to derive a justified price-to-book value.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Limitation: Terminal value is 74% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Solve for the growth rate that makes the model value equal the report-date share price.
Upside persists only if post-FY2027 earnings growth proves durable and the observed regional revenue breadth translates into steadier profit. Rising diluted shares or renewed margin weakness would disconfirm this path.6
Weak conversion would lower future earnings and residual value.
A lower denominator raises earnings per share for unchanged income.4
Weak profitability would keep the price paid for future earnings compressed.3
| $103.01B |
| $106.10B |
| $108.75B |
| Operating income | $22.29B | $23.16B | $23.97B | $24.69B | $25.30B |
| NOPAT | $16.36B | $17.00B | $17.60B | $18.12B | $18.58B |
| Residual cash after reinvestment policy | $16.36B | $17.00B | $17.60B | $18.12B | $18.58B |
| Revenue growth | 12.4% | 3.9% | 3.5% | 3.0% | 2.5% |
| Operating margin | 23.3% | 23.3% | 23.3% | 23.3% | 23.3% |
| Tax rate | 26.6% | 26.6% | 26.6% | 26.6% | 26.6% |
| Reinvestment rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Diluted shares | 1.83B | 1.79B | 1.76B | 1.72B | 1.68B |
| EPS | $10.45 | $12.88 | $13.00 | $13.01 | $12.94 |
| Net margin | 20.0% | 23.2% | 22.1% | 21.1% | 20.0% |
| Implied net income | $19.16B | $23.11B | $22.81B | $22.36B | $21.75B |
| Marża |
|---|
| C | Citigroup Inc. | $231.0B | 10.6x | 2.8x | 8.5% | — | |
| BAC | Bank of America Corporation | 11.8x | 3.8x | 11.2% | 38.3% | ||
| WFC | Wells Fargo & Company | 11.4x | 3.3x | 12.6% | 37.4% | ||
| AXP | American Express Company | 16.2x | 3.1x | 34.4% | 20.3% | ||
| SCHW | The Charles Schwab Corporation | 14.0x | 7.3x | 20.3% | 52.3% |
| FY2027 diluted shares | Above 1.8 billion | Remove buyback support from the thesis and remain out of the shares. |
